Pictet Asset Management (Switzerland)’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-16,130	Closed	-$67.7K	–	2066
2023 Q1	$67.7K	Buy	16,130 +4,596	+40%	+$23.9K	﹤0.01%	1925
2022 Q4	$69K	Buy	+11,534	New	+$63K	﹤0.01%	1934

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s CTIC Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 16,130 shares — an estimated $67.7K sold.

Pictet Asset Management (Switzerland) first reported a position in CTIC in Q4 2022 and held it in 2 quarters. The position peaked at $69K in Q4 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Pictet Asset Management (Switzerland) reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Pictet Asset Management (Switzerland) sold 16,130 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $67.7K.
Pictet Asset Management (Switzerland) first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2022 and held it in 2 quarters.
Pictet Asset Management (Switzerland)'s CTI BioPharma Corp. (DE) Common Stock position peaked at $69K in Q4 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.